Inetetamab combined with S-1 and oxaliplatin as first-line treatment for human epidermal growth factor receptor 2-positive gastric cancer
In the first-line treatment of HER2-positive advanced gastric cancer, inetetamab and trastuzumab showed comparable efficacy. The inetetamab group showed superior PFS, and both groups had good safety.
Authors
- Yi Miao (ORCID: https://orcid.org/0000-0003-0738-6041)
- Mingyan Li (ORCID: https://orcid.org/0000-0002-2982-3188)
- Haiyan Liu (ORCID: https://orcid.org/0009-0002-1452-6743)
- Jiangang Liu (ORCID: https://orcid.org/0000-0001-9866-8591)
- Li Ma (ORCID: https://orcid.org/0009-0006-5425-4470)
- Peng Jin (ORCID: https://orcid.org/0000-0002-5696-2095)
- Qi-Jun Yi
- Ying Kong
- Qi Dong
Institutions
- Affiliated Hospital of Taishan Medical University (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- World Journal of Gastroenterology
- Published
- 2024-10-16
- DOI
- https://doi.org/10.3748/wjg.v30.i40.4367
- Citations
- 3
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 1.26
Funders
- Shandong First Medical University